AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02850653 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Sampling of aqueous humour
Study NCT04431401 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim rTMS
Description: The device is made in London,UK
Study NCT01235104 — intervention group
Intervention type: PROCEDURE
Intervention: Total nephrectomy
Description: Total nephrectomy
Study NCT03074760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adenovirus
Description: Diagnostic test for the presence of the adenovirus in the population groups
Study NCT03074760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rotavirus
Description: Diagnostic test for the presence of the Rotavirus in the population groups
Study NCT02757209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spiromax (budesonide/formoterol)
Description: DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup
Study NCT03074760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: H. pylori
Description: Diagnostic test for the presence of H. pylori infection in the population groups
Study NCT04354896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxin
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH 0.4 to 4.6 mU/L, no change to dose; TSH ≥4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Study NCT02757209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Turbohaler (budesonide/formoterol)
Description: Turbohaler® (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate)- Symbicort® 160/4.5. Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week. Additional 8 weeks in one subgroup
Study NCT02757209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)
Description: Diskus® inhaler(50mcg salmeterol\&250/500mcg fluticasone propionate)-Seretide Diskus 50/250mcg® or 50/500mcg.Dose of 1inhalation twice a day for1 week.Additional 8 weeks in1subgroup
Study NCT04354896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
Study NCT02026310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.
Study NCT02026310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glargine and metformin
Study NCT02026310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glargine and metformin
Study NCT03862326 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: From lying to sitting to active exercises with focus on the pelvic floor
Study NCT02578862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT03862326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: From lying to sitting to active exercises with focus on the pelvic floor
Study NCT03096288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
Study NCT02578862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study NCT03096288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
Study NCT03645720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plastic cannula
Description: puncture using plastic cannula
Study NCT02690948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02690948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT01694914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: corneal graft
Study NCT01694914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal graft
Study NCT03857854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: treatment group
Study NCT03857854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo group
Study NCT01795677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolotinib
Description: Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
Study NCT01598532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedX Health Phototherapy (light therapy)
Description: The treatment period is 6 weeks (3x per week) for a total of 18 Transcranial LED treatments. Each treatment session is 30 minutes each.
Study NCT03873116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353 capsules
Description: BCX7353 capsules administered orally once daily
Study NCT02637960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedovapagon 2 mg
Description: One daily dose of 2 mg fedovapagon for 12 weeks
Study NCT02637960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One daily dose of placebo (matched to fedovapagon) for 12 weeks
Study NCT03873116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo capsules administered orally once daily
Study NCT00597220 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 (n-3 PUFA)
Description: 1 gram of n-3 PUFA containing DHA and EPA
Study NCT00597220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00458263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatotropin growth hormone recombinant human
Description: daily Sub Cutaneous injections
Study NCT00702221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant
Description: Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant given as 3 separate intramuscular injections into the arm, 21 days apart
Study NCT00702221 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CoVaccine HT™ adjuvant
Description: Given as three separate intramuscular injections into the arm, 21 days apart
Study NCT01698840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT01698840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00686413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: single dose, oral
Study NCT00686413 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 2-[18F]-F-A85380
Description: Single dose, IV
Study NCT01773044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alkalinized lidocaine
Description: recevied 0.05 mL/kg lidocaine with bicarbonate ( % 2 lidocaine 5 mL + 1 mL %8,4 NaHCO3+ 4 mL SF)
Study NCT01773044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 0.05 mL/kg lidocaine (% 2 lidocaine 5 mL + 5 mL SF),
Study NCT01773044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for alcalinized lidocaine)
Study NCT01780506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Study NCT01780506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TDF
Description: 150/150/200/300 mg FDC tablet administered orally once daily
Study NCT01780506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF Placebo
Description: Tablet administered orally once daily
Study NCT01780506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TAF Placebo
Description: Tablet administered orally once daily
Study NCT03013270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic-Resistance-Inspiratory
Description: Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1 Repetition Maximum (1RM) for quads training and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets) for 10 min, combined also with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 20 min (Aerobic (30min) + Resistance (10min) + Inspiratory (20min) = 60 min)
Study NCT03013270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic-Resistance
Description: Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1RM for quads training, pectoralis m, serratus anterior m, and latissimus dorsi m and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets).~(Aerobic (30min) + Resistance (30min) = 60 min)
Study NCT03013270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic-Inspiratory
Description: Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 30min (Aerobic (30min) + Inspiratory (30min) = 60 min)
Study NCT03013270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training
Description: Patients will be submitted to a 12 week, 3 times/week continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with callisthenics progressing to treadmill or bike (at the same intensity) for 30 min (Aerobic training = 60 min)
Study NCT03543644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar-sweetened beverage (SSB)
Description: SSBs will be provided to each participant. Participants will be able to choose their SSB of choice from the list in the protocol. They will be instructed to drink their usual SSB intake, study drinks provided, while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
Study NCT03543644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-nutritive sweetened beverages (NSB)
Description: NSBs will be provided to each participant. Participants will be be given the NSB equivalent to the usual SSB chosen from the list in the protocol. They will be instructed to replace their usual SSBs with the NSBs while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
Study NCT03543644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water will be provided to each participant. They will be instructed to replace their usual SSBs with the water while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
Study NCT00448123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Study Drug
Study NCT00448123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01786733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Study NCT01786733 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Study NCT03032393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-power
Description: Subjects will stand with hands on their hips, elbows pointing out and feet approximately one foot apart (high-power) for 20 seconds.
Study NCT03032393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-power
Description: Subjects will stand with hands and arms wrapping around the torso and feet together (low-power) for 20 seconds.
Study NCT03550599 — intervention group
Intervention type: OTHER
Intervention: Patients accessing to Radiotherapy Unit
Description: No intervention; information about patient and disease characteristics will be recorded as well as information about pain and analgesic treatment
Study NCT03114683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1
Description: IBI308 200mg/3 weeks
Study NCT01697917 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Total Gastrectomy or Proximal Gastrectomy
Study NCT00102609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1
Study NCT00102609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles
Study NCT00102609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
Study NCT00570050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diluent / Insulin
Description: Diluent (4 Weeks ) / Intranasal insulin (4 weeks)
Study NCT00570050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin / Diluent
Description: Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)
Study NCT02729532 — intervention group
Intervention type: DEVICE
Intervention: Xpert
Description: The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System
Study NCT02633904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteotomy
Description: Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
Study NCT02633904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-osteotomy
Description: Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
Study NCT03426891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenously (IV) every 3 weeks. The dose of pembrolizumab will remain the same throughout study treatment. During the maintenance phase, participants will receive pembrolizumab (for 12 months).
Study NCT03426891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose Escalation Level -1 vorinostat 100 mg/day by mouth on days 1-5 every week during radiotherapy starting on first day of radiotherapy and 300 mg/day 1 week on 1 week off after radiotherapy. Level 1:vorinostat 200 mg/day by mouth on day 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 300 mg/day 1 week on 1 week off after radiotherapy. Dose Escalation Level 2: vorinostat 300 mg/day by mouth on days 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 400 mg/day 1 week on 1 week off after radiotherapy. Dose Expansion:all participants will receive the same dose of vorinostat that was determined to be most tolerated dose. During the maintenance phase, participants will receive vorinostat (for 12 months).
Study NCT02621125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fertilix
Description: daily supplementation
Study NCT02621125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02348762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cysteine (as n-acetylcysteine) and Glycine
Description: Older subjects will be studied before and after receiving cysteine and glycine
Study NCT04343638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional nociception control
Description: While Intraoperative opioid will be administered by conventional clinical practice in control arm.
Study NCT04343638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANI monitor guided nociception control
Description: The intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50 in ANI-monitor guided nociception control arm.
Study NCT01599715 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Instructional DVD
Description: Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once.
Study NCT03426891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: All participants will receive standard Temozolomide: Temozolomide (chemotherapy) 75 mg/m\^2/day by mouth administered during the course of radiotherapy. Temozolomide will be administered continuously from Day 1 of radiotherapy to the last day of radiation. Maintenance Phase: temozolomide will start 4 weeks (+/- 3 days) after last dose of radiotherapy and will continue for 6 cycles post radiotherapy (150-200 mg/m\^2/day, days 1-5 every 4 weeks) as per standard of care. During the maintenance phase, participants will receive Temozolomide (for the first 6 months).
Study NCT03426891 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All participants will receive standard radiotherapy: a total dose of 60 Gy administered in daily doses of 2 Gy, typically on a 5 days on / 2 days off schedule over 6 - 7 weeks.
Study NCT01599715 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Bladder Health Class
Description: Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
Study NCT02829788 — intervention group
Intervention type: OTHER
Intervention: Non interventional
Description: Peroperative data collection
Study NCT02911415 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling collection
Description: It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
Study NCT00728689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ST-246 Days 1 - 3
Description: First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
Study NCT00728689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ST-246 Days 11 - 13
Description: Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
Study NCT03931031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
Study NCT00594360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise on Prescription
Description: Exercise two times a week for two months at a physiotherapist. Afterwards exercise one time a week at a physiotherapist and self-contained training one time a week for 2 months.
Study NCT00888446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tgAAC09
Study NCT00888446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Formulation buffer
Description: Sterile isotonic buffered salt solution
Study NCT02202954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guided Self-rehabilitation Contract
Description: In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary.